Literature DB >> 8876274

Suprapubic versus transurethral catheterisation of males undergoing pelvic colorectal surgery.

C D Ratnaval1, P Renwick, R Farouk, J R Monson, P W Lee.   

Abstract

A prospective, randomised double-blind trial of suprapubic (SPC) versus transurethral (TUC) catheterisation was undertaken in fifty consecutive male patients of median age 66 (range 32-81) years undergoing pelvic colorectal surgery. Twenty-four patients were randomised to SPC. Catheter removal times were comparable between the two groups: SPC = mean 7.2 (3-14) days; TUC = man 7.5 (2-13) days; P > 0.5. Acute urinary retention was recorded in 5 patients with SPC and 6 in the TUC group. Chronic retention with overflow was recorded in one TUC patient. Frequent voiding after catheter removal occurred in two SPC, and in eleven TUC patients (P < 0.05). Re-catheterization was required in two SPC, and seven TUC patients. One culture positive urinary tract infection occurred in the SPC, and three in the TUC groups. It is concluded that suprapubic catheterisation allows comparable controlled return of normal voiding with fewer bladder and urethral symptoms when compared with transurethral catheterisation.

Entities:  

Mesh:

Year:  1996        PMID: 8876274     DOI: 10.1007/s003840050038

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  2 in total

1.  Randomized controlled trial of tamsulosin for prevention of acute voiding difficulty after rectal cancer surgery.

Authors:  Je-Ho Jang; Sung-Bum Kang; Sung-Min Lee; Jun-Seok Park; Duck-Woo Kim; Soyeon Ahn
Journal:  World J Surg       Date:  2012-11       Impact factor: 3.352

2.  Management of postoperative bladder emptying after proctectomy in men for rectal cancer. A retrospective study of 190 consecutive patients.

Authors:  Cécile Bouchet-Doumenq; Jérémie H Lefevre; Malika Bennis; Najim Chafai; Emmanuel Tiret; Yann Parc
Journal:  Int J Colorectal Dis       Date:  2015-12-22       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.